Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Quinoxaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.39 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoxaline SCHEMBL9171618 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL9171633 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL30320908 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL5315 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL29355228 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL6928518 | 0.96 | ALDH1A1 (0.58) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL2359961 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL5358832 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL16053848 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB | |
| Quinoxaline SCHEMBL20610240 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTNCF1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433120-B | Spirofluorene derivative containing seven-membered ring, electron transport material, and organic electroluminescent element | 常州强力昱镭光电材料有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115433120-A | Spirofluorene derivative containing seven-membered ring, electron transport material and organic electroluminescent device | 常州强力昱镭光电材料有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-2173354-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| CN-101426502-A | Compounds, formulations and methods for treating or preventing inflammatory skin diseases | SANSROSA PHARMACEUTICAL DEV IN (US) | 2009-05-06 | — | — | CN | disclosed |
| WO-2009021083-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| US-6548499-B1 | N-(1-Azabicyclo(2.2.2)octanyl-3-pyridinyl)-3-(2-pyridinyl)-2 -quinoxalinamine, for example; treating various chemokine mediated diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |